Every 10-Q that DBV Technologies S.A. (DBVT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow DBVT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DBVT filings page.
DBV Technologies S.A. is a late-stage biopharmaceutical company developing the Viaskin epicutaneous patch platform, led by Viaskin Peanut for children with peanut allergy. For the quarter ended June 30, 2026, there was no product revenue; operating income of $0.7 million came solely from the French research tax credit.
Quarterly operating expenses were $51.3 million, including research and development of $31.2 million, sales and marketing of $5.5 million, and general and administrative of $14.6 million, reflecting scaling for Biologics License Application (BLA) execution and commercial launch preparedness. Net loss was $50.4 million for the quarter and $98.0 million for the first six months, with basic and diluted loss per share of $(0.12) and $(0.23), respectively.
Cash and cash equivalents totaled $174.9 million at June 30, 2026. Net cash used in operating activities was $101.7 million and in investing activities $0.9 million in the first half, partially offset by $89.0 million of financing inflows from warrant exercises linked to the March 2025 PIPE financing. Management estimates existing resources will fund operations into the third quarter of 2027. The company is preparing a BLA for Viaskin Peanut in children aged 4–7 years in the third quarter of 2026 and a potential toddler BLA in the second half of 2026, supported by expanded manufacturing agreements and commercialization letters of intent.
DBV Technologies S.A. reported a larger net loss as it ramps up development and commercial preparation for its Viaskin Peanut patch. For the three months ended March 31, 2026, net loss widened to $47.6 million from $27.1 million a year earlier, driven by a sharp increase in operating expenses.
Research and development spending rose to $33.4 million, sales and marketing to $4.8 million, and general and administrative costs to $10.5 million, reflecting expanded clinical activity, pre-commercial inventory build, and build‑out of U.S. commercial and corporate infrastructure. There was still no product revenue; operating income of $0.9 million came mainly from the French research tax credit.
Following a 2025 PIPE financing and warrant exercises, DBV ended the quarter with $229.2 million in cash and cash equivalents, up from $194.2 million at year‑end 2025. Management estimates this cash should fund operations into the second quarter of 2027, assuming current plans focused on Viaskin Peanut, although faster spending or new programs could shorten that runway.
DBV Technologies (DBVT) reported Q3 results and liquidity updates. Cash and cash equivalents were $69.8 million as of September 30, 2025. The company posted a Q3 net loss of $33.2 million and a nine‑month net loss of $102.1 million, driven mainly by R&D spending for the Viaskin Peanut program.
DBV closed a $125.5 million financing in April 2025 and established an ATM program of up to $150.0 million; after quarter‑end it sold 2,307,692 ADSs for gross proceeds of about $30 million on October 6, 2025. The company estimates its cash runway extends into the third quarter of 2026, yet it states these conditions raise substantial doubt about its ability to continue as a going concern. Operating cash use was $86.0 million for the first nine months; financing cash inflows were $117.1 million.
Clinical and regulatory milestones remain central: VITESSE Phase 3 topline results in children 4–7 are anticipated in the fourth quarter of 2025, and up to $181.4 million in additional gross proceeds may be received if warrants are exercised, subject to conditions. As of October 27, 2025, 169,113,619 ordinary shares were outstanding including treasury shares.